Skip to content
Research Article Open access CC BY 4.0

Real World Evidence of Bempedoic Acid on Efficacy and Safety in Patients with Uncontrolled LDL-c and at High Risk of CVD

S. Manoj, Jay Shah, Dilip Kumar, Akshaya Pradhan, Amit B. Kinare, Ashwani Kumar Sharma, M. S. Aditya, Ram Anil Raj, Akhter Amin Raina, Ashish Patel, Biswajit Das, Dipak Suresh Bathe, Sameer Muchhala, Kunal Jhaveri

Cardiology and Angiology: An International Journal · pp. 113–122 · Published 16 Jun 2023

10.9734/ca/2023/v12i4350

Abstract

Background and Objective: Cardiovascular disease (CVD) is a significant cause of morbidity and mortality worldwide, with high-risk patients requiring effective management to reduce their risk of cardiovascular events. Bempedoic acid is a novel therapeutic agent recently approved as an add-on therapy to statins in patients with uncontrolled LDL-c. Bempedoic acid inhibits cholesterol synthesis in the liver, which ultimately reduces the risk of cardiovascular events. Therefore, the present study aims to assess the efficacy and safety of bempedoic acid in patients with uncontrolled LDL-c (Previously on moderate or high-intensity statins) with a high risk of CVD in real-world settings. Methods: This is a multicenter, retrospective, observational study on the data of high-risk-CVD patients collected from Bempedoic Acid on Efficacy and Safety in patients (BEST) Registry. The clinical data of 140 patients who were already on statin therapy and were receiving Bempedoic acid at a dose of 180 mg, along with measurements of the level of LDL-c, HbA1c, HDL, TG, TC, PPPG, FPG, AST, ALT, serum creatinine was taken into consideration. The primary outcome includes a change in LDL-c level, and secondary outcomes involve a change in the level of HbA1c, HDL, TG, TC, PPPG, FPG, AST, ALT, and serum creatinine at week 12 and 24. Adverse events were reported at both time points. Results: A total of 140 patients were included in the present study with a mean age of 51.8 ± 9.2 years and had primary confirmed diagnosis of dyslipidemia with uncontrolled LDL-c. The mean levels of LDL-c decreased from the mean baseline value of 142.67 ± 46.49 mg/dL, to 106.78 ±33.92 mg/d; a statistically significant reduction by 23.23% (p < 0.01) at week 12. Similarly, at week 24, the mean LDL-c value reduced to 90.39 ± 38.89 mg/dL. A 33.38 % decrease was observed (p < 0.01). Other parameters such as non-HDL, FPG, PPPG, AST and serum creatinine also showed statistically significant reduction at week 12 and week 24.  Conclusion: The present study demonstrates that bempedoic acid is an effective add-on medication in lowering LDL-c levels in high-risk CVD patients with uncontrolled LDL-c.

ACL inhibitor Bempedoic Acid (BA) Cardiovascular Diseases (CVDs) dyslipidemia Low-Density Lipoprotein Cholesterol (LDL-c)

References (25)

  1. 1 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [DOI]
  2. 2 Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes [DOI]
  3. 3 Global atlas on cardiovascular disease prevention and control.
  4. 4 Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome [DOI]
  5. 5 Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients [DOI]
  6. 6 A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke [DOI]
  7. 7 Prevalence of statin intolerance: a meta-analysis [DOI]
  8. 8 Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance [DOI]
  9. 9 Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study [DOI]
  10. 10 Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy [DOI]
  11. 11 AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism [DOI]
  12. 12 Role of Bempedoic Acid in Clinical Practice [DOI]
  13. 13 Total and High-density Lipoprotein Cholesterol in Adults: United States, 2015-2016.
  14. 14 Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial [DOI]
  15. 15 Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials [DOI]
  16. 16 Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study) [DOI]
  17. 17 2019 vs. 2016 ESC/EAS statin guidelines for primary prevention of atherosclerotic cardiovascular disease [DOI]
  18. 18 Evolocumab in Patients with Cardiovascular Disease [DOI]
  19. 19 A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia [DOI]
  20. 20 Total and High-density Lipoprotein Cholesterol in Adults: United States, 2011-2014.
  21. 21 Targeted next-generation sequencing to diagnose disorders of HDL cholesterol [DOI]
  22. 22 Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside [DOI]
  23. 23 Role of Lipid-Lowering Therapy in Low-Density Lipoprotein Cholesterol Goal Attainment: Focus on Patients With Acute Coronary Syndrome [DOI]
  24. 24 A comparison of two LDL cholesterol targets after ischemic stroke [DOI]
  25. 25 Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes [DOI]

Cited by 3

Effectiveness, safety, and treatment persistence of bempedoic acid in a Spanish real-world cohort.

D. León-Jiménez, S. Martínez-Hervás, Nagore Lois-Martínez · Journal of Clinical Lipidology · 2026

Role of bempedoic acid in secondary prevention of atherosclerotic cardiovascular disease patients: A prospective observational study

Gargi Gupta, Suyog Sindhu, Ayush Jain · Indian journal of physiology and pharmacology · 2026

Showing 2 of 3 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

51

Page views

0

PDF downloads

27

Outbound clicks

3

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.